How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? / Sørensen, Per Soelberg.

I: European Journal of Neurology, Bind 16, Nr. 3, 2009, s. 287-288.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sørensen, PS 2009, 'How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?', European Journal of Neurology, bind 16, nr. 3, s. 287-288.

APA

Sørensen, P. S. (2009). How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? European Journal of Neurology, 16(3), 287-288.

Vancouver

Sørensen PS. How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? European Journal of Neurology. 2009;16(3):287-288.

Author

Sørensen, Per Soelberg. / How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?. I: European Journal of Neurology. 2009 ; Bind 16, Nr. 3. s. 287-288.

Bibtex

@article{83538d405c0f11df928f000ea68e967b,

title = "How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?",

abstract = "Udgivelsesdato: 2009/3",

author = "S{\o}rensen, {Per Soelberg}",

year = "2009",

language = "English",

volume = "16",

pages = "287--288",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "3",